Cargando…
The spleen in liver cirrhosis: revisiting an old enemy with novel targets
The spleen is a secondary lymphoid organ which can influence the progression of multiple diseases, notably liver cirrhosis. In chronic liver diseases, splenomegaly and hypersplenism can manifest following the development of portal hypertension. These splenic abnormalities correlate with and have bee...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442653/ https://www.ncbi.nlm.nih.gov/pubmed/28535799 http://dx.doi.org/10.1186/s12967-017-1214-8 |
_version_ | 1783238436443914240 |
---|---|
author | Li, Liang Duan, Mubing Chen, Weisan Jiang, An Li, Xiaoming Yang, Jun Li, Zongfang |
author_facet | Li, Liang Duan, Mubing Chen, Weisan Jiang, An Li, Xiaoming Yang, Jun Li, Zongfang |
author_sort | Li, Liang |
collection | PubMed |
description | The spleen is a secondary lymphoid organ which can influence the progression of multiple diseases, notably liver cirrhosis. In chronic liver diseases, splenomegaly and hypersplenism can manifest following the development of portal hypertension. These splenic abnormalities correlate with and have been postulated to facilitate the progression of liver fibrosis to cirrhosis, although precise mechanisms remain poorly understood. In this review, we summarize the literature to highlight the mechanistic contributions of splenomegaly and hypersplenism to the development of liver cirrhosis, focusing on three key aspects: hepatic fibrogenesis, hepatic immune microenvironment dysregulation and liver regeneration. We conclude with a discussion of the possible therapeutic strategies for modulating splenic abnormalities, including the novel potential usage of nanomedicine in non-surgically targetting splenic disorders for the treatment of liver cirrhosis. |
format | Online Article Text |
id | pubmed-5442653 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-54426532017-05-25 The spleen in liver cirrhosis: revisiting an old enemy with novel targets Li, Liang Duan, Mubing Chen, Weisan Jiang, An Li, Xiaoming Yang, Jun Li, Zongfang J Transl Med Review The spleen is a secondary lymphoid organ which can influence the progression of multiple diseases, notably liver cirrhosis. In chronic liver diseases, splenomegaly and hypersplenism can manifest following the development of portal hypertension. These splenic abnormalities correlate with and have been postulated to facilitate the progression of liver fibrosis to cirrhosis, although precise mechanisms remain poorly understood. In this review, we summarize the literature to highlight the mechanistic contributions of splenomegaly and hypersplenism to the development of liver cirrhosis, focusing on three key aspects: hepatic fibrogenesis, hepatic immune microenvironment dysregulation and liver regeneration. We conclude with a discussion of the possible therapeutic strategies for modulating splenic abnormalities, including the novel potential usage of nanomedicine in non-surgically targetting splenic disorders for the treatment of liver cirrhosis. BioMed Central 2017-05-23 /pmc/articles/PMC5442653/ /pubmed/28535799 http://dx.doi.org/10.1186/s12967-017-1214-8 Text en © The Author(s) 2017 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Review Li, Liang Duan, Mubing Chen, Weisan Jiang, An Li, Xiaoming Yang, Jun Li, Zongfang The spleen in liver cirrhosis: revisiting an old enemy with novel targets |
title | The spleen in liver cirrhosis: revisiting an old enemy with novel targets |
title_full | The spleen in liver cirrhosis: revisiting an old enemy with novel targets |
title_fullStr | The spleen in liver cirrhosis: revisiting an old enemy with novel targets |
title_full_unstemmed | The spleen in liver cirrhosis: revisiting an old enemy with novel targets |
title_short | The spleen in liver cirrhosis: revisiting an old enemy with novel targets |
title_sort | spleen in liver cirrhosis: revisiting an old enemy with novel targets |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442653/ https://www.ncbi.nlm.nih.gov/pubmed/28535799 http://dx.doi.org/10.1186/s12967-017-1214-8 |
work_keys_str_mv | AT liliang thespleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT duanmubing thespleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT chenweisan thespleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT jiangan thespleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT lixiaoming thespleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT yangjun thespleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT lizongfang thespleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT liliang spleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT duanmubing spleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT chenweisan spleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT jiangan spleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT lixiaoming spleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT yangjun spleeninlivercirrhosisrevisitinganoldenemywithnoveltargets AT lizongfang spleeninlivercirrhosisrevisitinganoldenemywithnoveltargets |